JP2012511545A5 - - Google Patents

Download PDF

Info

Publication number
JP2012511545A5
JP2012511545A5 JP2011540102A JP2011540102A JP2012511545A5 JP 2012511545 A5 JP2012511545 A5 JP 2012511545A5 JP 2011540102 A JP2011540102 A JP 2011540102A JP 2011540102 A JP2011540102 A JP 2011540102A JP 2012511545 A5 JP2012511545 A5 JP 2012511545A5
Authority
JP
Japan
Prior art keywords
human
polypeptide according
variable domain
single variable
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011540102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012511545A (ja
JP5823871B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/066822 external-priority patent/WO2010066836A2/en
Publication of JP2012511545A publication Critical patent/JP2012511545A/ja
Publication of JP2012511545A5 publication Critical patent/JP2012511545A5/ja
Application granted granted Critical
Publication of JP5823871B2 publication Critical patent/JP5823871B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011540102A 2008-12-10 2009-12-10 血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン／Ｔｉｅシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド Expired - Fee Related JP5823871B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12122808P 2008-12-10 2008-12-10
US61/121,228 2008-12-10
PCT/EP2009/066822 WO2010066836A2 (en) 2008-12-10 2009-12-10 Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis

Publications (3)

Publication Number Publication Date
JP2012511545A JP2012511545A (ja) 2012-05-24
JP2012511545A5 true JP2012511545A5 (cg-RX-API-DMAC7.html) 2013-01-24
JP5823871B2 JP5823871B2 (ja) 2015-11-25

Family

ID=42026361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540102A Expired - Fee Related JP5823871B2 (ja) 2008-12-10 2009-12-10 血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン／Ｔｉｅシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド

Country Status (7)

Country Link
US (3) US8858940B2 (cg-RX-API-DMAC7.html)
EP (1) EP2364328A2 (cg-RX-API-DMAC7.html)
JP (1) JP5823871B2 (cg-RX-API-DMAC7.html)
CN (1) CN102307902B (cg-RX-API-DMAC7.html)
AU (2) AU2009324354B2 (cg-RX-API-DMAC7.html)
CA (1) CA2746395C (cg-RX-API-DMAC7.html)
WO (1) WO2010066836A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US20110189206A1 (en) 2008-01-03 2011-08-04 Barbas Iii Carlos F Antibody Targeting Through a Modular Recognition Domain
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
CN102307902B (zh) 2008-12-10 2016-02-24 埃博灵克斯股份有限公司 用于治疗与血管发生相关的疾病和病症的针对血管生成素/Tie系统的氨基酸序列和包括其的多肽
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
DK2831111T3 (en) * 2012-03-30 2019-04-29 Boehringer Ingelheim Int Ang2-binding molecules
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
KR102131371B1 (ko) 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
AP2017009721A0 (en) 2014-08-07 2017-01-31 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
MA41899A (fr) 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne
JP6916776B2 (ja) * 2015-07-29 2021-08-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｎｇ−２に対する重鎖のみ抗体
KR20190084287A (ko) * 2016-11-14 2019-07-16 노파르티스 아게 연골 손상 및 관절염 치료 방법 및 조성물
CA3049727C (en) * 2017-01-13 2022-10-04 Vasomune Therapeutics Inc. An agent for promoting angiogenesis and methods and uses thereof
KR101955886B1 (ko) * 2017-05-05 2019-03-12 주식회사 유비프로틴 안지오포이에틴-1 반감기를 증가시키는 방법
EP4061852A4 (en) * 2019-11-21 2024-03-13 Unity Biotechnology ANTIBODIES AGAINST TIE-2 AND METHODS OF USE
US20240425575A1 (en) * 2021-09-10 2024-12-26 Soter Biopharma Pte. Ltd Anti-ang2 antibody, preparation method therefor, and application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US6365154B1 (en) 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
JP2007528720A (ja) * 2003-08-12 2007-10-18 ダイアックス コーポレイション Ｔｉｅ１結合リガンド
AU2003264053A1 (en) 2003-08-12 2005-03-10 William M. Yarbrough Treatment for acne vulgaris and method of use
ES2364147T3 (es) * 2004-01-16 2011-08-25 Regeneron Pharmaceuticals, Inc. Polipéptidos de fusión capaces de activar receptores.
WO2006005361A1 (en) 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2636854A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
AU2007227251A1 (en) 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
JP2010500876A (ja) * 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer
US20110091473A1 (en) * 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
MX2010005783A (es) * 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EP2285408B1 (en) * 2008-06-05 2018-10-24 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
CN102307902B (zh) 2008-12-10 2016-02-24 埃博灵克斯股份有限公司 用于治疗与血管发生相关的疾病和病症的针对血管生成素/Tie系统的氨基酸序列和包括其的多肽

Similar Documents

Publication Publication Date Title
JP2012511545A5 (cg-RX-API-DMAC7.html)
Shyu et al. Homing genes, cell therapy and stroke
EP4378487A3 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
JP2016521688A5 (cg-RX-API-DMAC7.html)
EP4272728A3 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
WO2020057541A8 (en) Anti-ifnar1 antibodies for treating autoimmune diseases
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
JP2013107899A5 (cg-RX-API-DMAC7.html)
WO2009044273A3 (en) Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP2017537612A5 (cg-RX-API-DMAC7.html)
JP2018511327A5 (cg-RX-API-DMAC7.html)
EP3308798A3 (en) Polypeptides and antibodies for treating hbv infection and related diseases
JP2016502515A5 (cg-RX-API-DMAC7.html)
JP2017523985A5 (cg-RX-API-DMAC7.html)
JP2014513941A5 (cg-RX-API-DMAC7.html)
JP2006506942A5 (cg-RX-API-DMAC7.html)
JP2014525394A5 (cg-RX-API-DMAC7.html)
NZ599930A (en) Pharmaceutical compositions for the stimulation of stem cells.
JP2019531293A5 (cg-RX-API-DMAC7.html)
RU2021130306A (ru) Композиции il-12, нацеленные на edb
JP2014050390A5 (cg-RX-API-DMAC7.html)
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
JP2016513471A5 (cg-RX-API-DMAC7.html)
ZA202201828B (en) Therapeutic fusion proteins
CL2007003754A1 (es) Compuestos derivados de aril(heteroaril)alquil-amina; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como bronquitis, enfisema pulmonar y epoc.